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Rapamycin and HIV Replication in Liver Transplant Recipients
We appreciate the concerns from
Baccarani et al. regarding the active
replication of HIV among our series of
patients in calcineurin inhibitor im-
munosuppressive treatment after liver
transplantation (LT). To better under-
stand the experience of Baccarani et al.,
it would be necessary to have more de-
tailed data, such as antiretroviral (ARV)
therapy adopted, HIV viral load (VL) at
different time points from transplanta-
tion to the last check, and HIV VL of all
patients of their series. An important
difference between our experience and
the experience of Baccarani et al. seems
to be the switch time from calcineurin
inhibitor to rapamycin. Indeed, the me-
dian time of immunosuppression switch
in the patient cohort of Baccarani et al.
was significantly longer then in our
experience.
HIV VL control is mandatory for
the success of patient and organ survival
postorthotopic liver transplantation, and
this is a matter of the choice of the best
ARV therapy available independently of
the type of antirejection treatment. In this
perspective, we also discourage LT in pa-
tients with no effective ARV option post-
LT. Never the less the questions “when”
and “what to start” ARV post-LT are still
open and our experiencemeant to under-
line that rapamycin ability to inhibit HIV
replication needs to be considered while
tailoring ARV post-LT.
In our series, most patients had un-
detectable HIV VL after transplantation;
however, two patients developed HIV re-
activation, although they were on a triple
ARVtherapy. Instead,HIVreplicationdid
not occur among the rapamycin group.
However, based on the experiences re-
ported in the literature (1–5), nobody
could know whether rapamycin is really
effective inHIVreplicationcontrol among
liver transplant recipients. Since the
study by Heredia et al. (4), our impres-
sion, from a preliminary analysis of a set
of liver transplant HIV recipients, is
that rapamycin may allow a better con-
trol of HIV replication. We hypothe-
sized that rapamycin contributed to a
more rapid ability to obtain VL unde-
tectable in patients with VL rebound
secondary to ARV interruption in the
early postorthotopic liver transplanta-
tion period.
To definitively establish a base-
line on this topic, a prospective study
with a larger patient cohort and with
more appropriate clinical tests (such
as CCR5 count on the lymphocyte sur-
face) is necessary. We also believe that
future studies may be able to specifi-
cally investigate the potential advan-
tage of rapamycin in HIV VL kinetics,
in reducing HIV residual viremia in
patients with undetectable VL, and in
the reduction of hepatitis C virus re-
currence.
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The Spleen as a Site for Hematopoiesis
We read with interest the recent
article by Tan and O’Neill in Transplan-
tation (1). On the basis of a spleen trans-
plant experiment in allotype-distinct
recipient mice, they describe the role
of this organ as a site for endogenous
myelopoiesis. Although the role of
the spleen as an extramedullary site
of hematopoiesis is well established
in this species, it has remained uncer-
tain whether this can be extrapolated
to humans.
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